ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

1.11
-0.17
(-13.28%)
Closed December 24 4:00PM
1.1115
0.0015
(0.14%)
After Hours: 7:53PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.1115
Bid
1.11
Ask
1.15
Volume
1,287,596
1.1011 Day's Range 1.25
0.5001 52 Week Range 1.93
Market Cap
Previous Close
1.28
Open
1.25
Last Trade Time
Financial Volume
$ 1,503,295
VWAP
1.1675
Average Volume (3m)
421,779
Shares Outstanding
43,958,074
Dividend Yield
-
PE Ratio
-0.64
Earnings Per Share (EPS)
-1.74
Revenue
-
Net Profit
-76.4M

About Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was $1.28. Over the last year, Xilio Therapeutics shares have traded in a share price range of $ 0.5001 to $ 1.93.

Xilio Therapeutics currently has 43,958,074 shares outstanding. The market capitalization of Xilio Therapeutics is $56.27 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.64.

XLO Latest News

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GIย 

Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed...

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics Announces Inducement Grants Underย Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with...

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024ย Financial Results

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at...

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.117311.79843089920.99421.280.823523827441.13021605CS
40.206722.84482758620.90481.280.82356949721.11844687CS
120.35246.34628044770.75951.540.71134217791.12897426CS
260.211523.50.91.540.6812709641.05389339CS
520.511585.250.61.930.50015263701.1232792CS
156-12.7685-91.99207492813.8816.92840.492101061.53232048CS
260-13.8885-92.591527.950.492095842.24406939CS

XLO - Frequently Asked Questions (FAQ)

What is the current Xilio Therapeutics share price?
The current share price of Xilio Therapeutics is $ 1.1115
How many Xilio Therapeutics shares are in issue?
Xilio Therapeutics has 43,958,074 shares in issue
What is the market cap of Xilio Therapeutics?
The market capitalisation of Xilio Therapeutics is USD 56.27M
What is the 1 year trading range for Xilio Therapeutics share price?
Xilio Therapeutics has traded in the range of $ 0.5001 to $ 1.93 during the past year
What is the PE ratio of Xilio Therapeutics?
The price to earnings ratio of Xilio Therapeutics is -0.64
What is the reporting currency for Xilio Therapeutics?
Xilio Therapeutics reports financial results in USD
What is the latest annual profit for Xilio Therapeutics?
The latest annual profit of Xilio Therapeutics is USD -76.4M
What is the registered address of Xilio Therapeutics?
The registered address for Xilio Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Xilio Therapeutics website address?
The website address for Xilio Therapeutics is xiliotx.com
Which industry sector does Xilio Therapeutics operate in?
Xilio Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRCTDirect Digital Holdings Inc
$ 5.25
(854.55%)
68.54M
CHEKCheck Cap Ltd
$ 2.24
(279.66%)
40.03M
SLGLSol Gel Technologies Ltd
$ 1.57
(265.97%)
18.2M
RELIReliance Global Group Inc
$ 3.08
(156.67%)
105.56M
TRAWTraws Pharma Inc
$ 12.50
(149.00%)
28.23M
AILEiLearningEngines Inc
$ 0.199
(-77.51%)
29.69M
MGOLMGO Global Inc
$ 0.4765
(-49.84%)
14.08M
YHCLQR House Inc
$ 1.11
(-36.57%)
1.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
192.3M
ADGMAdagio Medical Holdings Inc
$ 1.095
(-33.64%)
4.84M
EDBLEdible Garden AG Inc
$ 0.3669
(54.35%)
408.02M
RGTIRigetti Computing Inc
$ 10.945
(16.81%)
223.51M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
192.3M
NVDANVIDIA Corporation
$ 139.67
(3.69%)
174.65M
RIMEAlgorhythm Holdings Inc
$ 0.0925
(21.07%)
155.8M

XLO Discussion

View Posts
tbonaces80 tbonaces80 4 days ago

Here it is
๐Ÿ‘๏ธ0
tbonaces80 tbonaces80 4 days ago
Bullish pennant on continuation. Thank me later
👍️ 1
tbonaces80 tbonaces80 4 days ago
Strike is easily $1.97. News or approval and we go hard
๐Ÿ‘๏ธ0
tbonaces80 tbonaces80 4 days ago
Loaded a nice position here
๐Ÿ‘๏ธ0
Preciouslife1 Preciouslife1 4 days ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-present-initial-phase-2-data-vilastobart
👍 1
PonkenPlonken PonkenPlonken 3 weeks ago
trades below cash value
Makes no f in sense!
stick it out......
👍️ 1
Preciouslife1 Preciouslife1 2 months ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
XLO HERE WE GO
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
BIO BEAST
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
XLO MONSTER BREAK
👍 1
TrendTrade2016 TrendTrade2016 2 months ago
XLO BUILDING STEAM
👍 1
PonkenPlonken PonkenPlonken 2 months ago
running towards two readouts with Gilead sitting at 17% ownership at 1.97$ strike. I have the hubris to say this WILL GO GO
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
XLO HERE WE GO
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 2 months ago
COMING TO LIFE
masked antibodies
👍 1
TrendTrade2016 TrendTrade2016 2 months ago
XLO...MINI BIO BEAST
👍 1
Laster Laster 2 months ago
Got some at $1.00 several days ago.
I like the share structure. It might run for a few days.
Looking for $1.40 if I am lucky.
👍️ 1
Preciouslife1 Preciouslife1 2 months ago
https://ir.xiliotx.com/news-and-events/news-releases
👍️ 1
Preciouslife1 Preciouslife1 3 months ago
https://www.linkedin.com/posts/hashem-al-ghaili-1b30679b_drug-resistant-bacteria-are-projected-to-activity-7246464071565201410-sAL9?utm_source=share&utm_medium=member_ios
๐Ÿ‘๏ธ0
Preciouslife1 Preciouslife1 4 months ago
This information makes one wonder IF BRILICIDIN IS BEING SUPPRESSED TOO: https://www.facebook.com/share/r/MTAzjcdR5iGnab4t/?mibextid=6GsUZ4
👍️ 1
Preciouslife1 Preciouslife1 4 months ago
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 months ago
Gilead paid 13.5mn$ @ 1.97
The results of their partnered program and another one will be reported in Q4 24
masked antibodies... very little toxicity.
I have a small position... Think big rally coming into 2025- atleast to the 1.97 strike.


"Under the License Agreement, the Company will receive approximately $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of approximately $13.5 million in the Companyโ€™s common stock, $0.0001 par value per share (the โ€œCommon Stockโ€), at a purchase price of $1.97 per share. The Company will be eligible to receive up to $604.0 million in additional contingent payments, which include (i) the proceeds from up to three additional private placements of Common Stock, (ii) the $75.0 million transition fee and (iii) specified development, regulatory and sales-based milestones. Prior to the potential transition fee, up to $29.0 million of the total contingent payments are related to the potential additional private placements of Common Stock and a near-term development milestone. In addition, the Company is eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."

"In addition, through March 27, 2025, the Company may, at its election and subject to the terms and conditions of the Stock Purchase Agreement, cause Gilead to purchase up to approximately $11.5 million of additional shares of Common Stock (including, at Gileadโ€™s sole election, prefunded warrants in lieu of shares of Common Stock) in up to three additional private placements (each, an โ€œAdditional Gilead Private Placementโ€) at a predetermined price per share..."
👍️ 1
PonkenPlonken PonkenPlonken 7 months ago
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
๐Ÿ‘๏ธ0
Preciouslife1 Preciouslife1 7 months ago
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
๐Ÿ‘๏ธ0
Laster Laster 8 months ago
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
XLO under $2
๐Ÿ‘๏ธ0
Laster Laster 8 months ago
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
๐Ÿ‘๏ธ0
Laster Laster 8 months ago
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
๐Ÿ‘๏ธ0
Laster Laster 8 months ago
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
๐Ÿ‘๏ธ0
Awl416 Awl416 9 months ago
Donโ€™t blink
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 9 months ago
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
๐Ÿ‘๏ธ0
TIMGZ TIMGZ 9 months ago
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 9 months ago
XLO: Worthless piece of SHIT!!!
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 9 months ago
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 9 months ago
XLO: Halted.
๐Ÿ‘๏ธ0
JPetroInc JPetroInc 9 months ago
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders โ€ฆ

EOM
๐Ÿ‘๏ธ0
Awl416 Awl416 9 months ago
Watch out for these dirty algoโ€™s
๐Ÿ‘๏ธ0
Awl416 Awl416 9 months ago
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
๐Ÿ‘๏ธ0
Awl416 Awl416 9 months ago
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 3 years ago
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 3 years ago
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 3 years ago
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock